Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome:post hocanalysis of patients with early Parkinson’s disease with mild symptom severity

2015 ◽  
Vol 16 (10) ◽  
pp. 1423-1433 ◽  
Author(s):  
Lars Timmermann ◽  
Mahnaz Asgharnejad ◽  
Babak Boroojerdi ◽  
Elisabeth Dohin ◽  
Franz Woltering ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Symptom Severity ◽  
Mild Symptom ◽  
Early Parkinson’S Disease

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

2009 ◽  
Vol 24 (4) ◽  
pp. 564-573 ◽  
Author(s):  
Robert A. Hauser ◽  
Mark F. Lew ◽  
Howard I. Hurtig ◽  
William G. Ondo ◽  
Joanne Wojcieszek ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Early Parkinson’S Disease

scholarly journals Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease

2019 ◽  
Vol 126 (3) ◽  
pp. 299-308 ◽  
Author(s):  
Nobutaka Hattori ◽  
Atsushi Takeda ◽  
Shinichi Takeda ◽  
Akira Nishimura ◽  
Tadayuki Kitagawa ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Japanese Patients ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Early Parkinson’S Disease

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

2012 ◽  
Vol 20 (2) ◽  
pp. 271-280 ◽  
Author(s):  
A. H. V. Schapira ◽  
F. Stocchi ◽  
R. Borgohain ◽  
M. Onofrj ◽  
M. Bhatt ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Early Parkinson’S Disease

Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease

2011 ◽  
Vol 121 (5) ◽  
pp. 246-253 ◽  
Author(s):  
Robert A. Hauser ◽  
Heinz Reichmann ◽  
Mark Lew ◽  
Afsaneh Asgharian ◽  
Clare Makumi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prolonged Release ◽  
Open Label ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Early Parkinson’S Disease

Long-Term Efficacy of Rasagiline in Early Parkinson's Disease

2010 ◽  
Vol 120 (6) ◽  
pp. 404-408 ◽  
Author(s):  
Mark F. Lew ◽  
Robert A. Hauser ◽  
Howard I. Hurtig ◽  
William G. Ondo ◽  
Joanne Wojcieszek ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Efficacy ◽  
Early Parkinson’S Disease

Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease

2008 ◽  
Vol 21 (4) ◽  
pp. 244-253 ◽  
Author(s):  
Jack J. Chen ◽  
Rajesh Pahwa
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Agonists ◽  
Initial Therapy ◽  
Motor Complications ◽  
Type B ◽  
Early Parkinson’S Disease ◽  
Monoamine Oxidase Type B

The most efficacious symptomatic agent for Parkinson's disease is levodopa; however, the development of motor complications with long-term therapy is concerning. In the modern day treatment of Parkinson's disease, non-levodopa agents (eg, dopamine agonists, monoamine oxidase type B inhibitors) should be considered as appropriate initial treatments. In early Parkinson's disease, dopamine agonists provide effective symptomatic therapy, reduce the risk for motor complications, and delay the need to initiate levodopa. However, the dopamine agonists are associated with impulse control disorders and behaviors that are concerning. Monoamine oxidase type B inhibitors are also effective as monotherapy for early stage Parkinson's disease. Clinical data demonstrate that early initiation of rasagiline (in the absence of functional impairment) is associated with improved outcomes as opposed to delayed initiation. Selegiline can delay the need for levodopa, albeit its clinical effectiveness as monotherapy is equivocal. When selecting initial therapy for early Parkinson's disease, clinicians must consider both short-term and long-term benefits and risks.

Sign in / Sign up

Export Citation Format

Share Document